Mechanism of Action
Mitochondrial Calcium and ROS Regulation
STC1 localizes to mitochondria in addition to being secreted. Mitochondrial STC1 reduces superoxide production by promoting mild uncoupling, reducing mitochondrial membrane potential and ROS generation without fully impairing ATP synthesis. This "mitohormetic" mechanism protects cells during ischemia-reperfusion, oxygen-glucose deprivation, and other stressors. STC1 also interacts with PGRMC2 (progesterone receptor membrane component 2) to modulate calcium handling.
Hypoxia Inducible Factor and Angiogenesis
STC1 expression is strongly upregulated by HIF-1alpha during hypoxia. In turn, STC1 promotes angiogenesis by upregulating VEGF and reducing the expression of anti-angiogenic factors. This HIF-STC1-VEGF axis positions STC1 as a link between hypoxic stress sensing and the adaptive vascular response. In cancer, STC1 upregulation promotes tumor vascularization and correlates with aggressive disease.
Research Summary
Ischemia-Reperfusion Protection
Active ResearchIP STC1 reduces infarct size in myocardial ischemia-reperfusion models by 40-50%. Renal ischemia-reperfusion: STC1 knockout mice show greater acute kidney injury; recombinant STC1 administration reduces tubular cell death and inflammation. Neuroprotective effects in stroke and TBI models via mitochondrial ROS reduction and anti-apoptotic signaling.
Cancer Biology
Active ResearchSTC1 is overexpressed in breast, colon, prostate, and ovarian cancers, correlating with poor prognosis. STC2 (a related protein) is an ERK effector in breast cancer promoting growth factor signaling. Anti-STC1/STC2 antibody approaches and small molecules targeting STC signaling are in early oncology research. The same cytoprotective effects that are beneficial in normal tissue may enable cancer cell survival under hypoxic stress.
Calculate your Stanniocalcin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Ischemia protection research | 5-50 mcg/kg IP or IV in rodent I/R models | Single dose at reperfusion | Intraperitoneal or intravenous |
Recombinant human STC1 is available for research but not clinically approved. Primary research application is understanding cytoprotective and tissue-injury mechanisms; therapeutic translation is early stage.
Interactions
Safety Profile
No human pharmacological data. Systemic STC1 overexpression in mice causes growth retardation and impaired fertility via growth plate chondrocyte and reproductive effects. These growth-limiting effects would be concerns for therapeutic use. However, short-term administration for acute ischemia protection may avoid chronic developmental effects. Cancer-promoting potential in STC1-overexpressing tumors represents a theoretical concern for any STC1 agonist approach. Research is currently at mechanistic characterization stage.
References
- [1]Chang AC, et al. Mammalian stanniocalcin-1 activates mitochondrial antioxidant pathways: new paradigms for regulation of macrophages and endothelium. Am J Physiol Regul Integr Comp Physiol. 2005;289(2):R329-R335.
- [2]Deol HK, et al. Stanniocalcin 1 promotes migration of breast cancer cells through activation of PI3K/Akt. PLoS One. 2015;10(1):e0117080.